These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. HIV-specific cytotoxic T lymphocytes and their possible implications in the future vaccine against AIDS. Langlade-Demoyen P; Hoffenbach A Res Immunol; 1989 Jan; 140(1):95-9; discussion 119-20. PubMed ID: 2567045 [No Abstract] [Full Text] [Related]
3. A strategy for prophylactic vaccination against HIV. Salk J; Bretscher PA; Salk PL; Clerici M; Shearer GM Science; 1993 May; 260(5112):1270-2. PubMed ID: 8098553 [No Abstract] [Full Text] [Related]
5. What are the correlates of protection? Cohen J Science; 1993 May; 260(5112):1259. PubMed ID: 8493565 [No Abstract] [Full Text] [Related]
6. Biological significance of the antibody response to HIV antigens expressed on the cell surface. Goudsmit J; Ljunggren K; Smit L; Jondal M; Fenyƶ EM Arch Virol; 1988; 103(3-4):189-206. PubMed ID: 3265052 [TBL] [Abstract][Full Text] [Related]
7. Antigenic structures recognized by T cells: towards the rational design of an AIDS vaccine. Cease KB; Berzofsky JA AIDS; 1988; 2 Suppl 1():S95-101. PubMed ID: 3147685 [No Abstract] [Full Text] [Related]
8. Immunology in AIDS in 1990. Sela M AIDS; 1990; 4 Suppl 1():S9-14. PubMed ID: 1983804 [No Abstract] [Full Text] [Related]
9. Is an effective HIV vaccine feasible? Cohen J Science; 2005 Jul; 309(5731):99. PubMed ID: 15994545 [No Abstract] [Full Text] [Related]
10. Challenges in the search for an HIV vaccine. Lemckert AA; Goudsmit J; Barouch DH Eur J Epidemiol; 2004; 19(6):513-6. PubMed ID: 15330122 [TBL] [Abstract][Full Text] [Related]
11. Challenges and opportunities for development of an AIDS vaccine. Nabel GJ Nature; 2001 Apr; 410(6831):1002-7. PubMed ID: 11309631 [TBL] [Abstract][Full Text] [Related]
12. Use of vaccinia virus vectors for development of AIDS vaccines. Moss B AIDS; 1988; 2 Suppl 1():S103-5. PubMed ID: 3147660 [No Abstract] [Full Text] [Related]
13. Will antibody-dependent enhancement of HIV-1 infection be a problem with AIDS vaccines? Robinson WE; Montefiori DC; Mitchell WM Lancet; 1988 Apr; 1(8589):830-1. PubMed ID: 2895350 [No Abstract] [Full Text] [Related]
14. Cytotoxic T-cell recognition of HIV proteins and peptides. Nixon DF; McMichael AJ AIDS; 1991 Sep; 5(9):1049-59. PubMed ID: 1718319 [No Abstract] [Full Text] [Related]
15. AIDS vaccine. Minn Med; 1991 Mar; 74(3):46. PubMed ID: 2030681 [No Abstract] [Full Text] [Related]
16. Human trials of experimental AIDS vaccines: recombinant envelope proteins. Snart RS AIDS; 1988; 2 Suppl 1():S107-11. PubMed ID: 2906544 [No Abstract] [Full Text] [Related]
17. The immunopathogenesis of HIV infection. Rosenberg ZF; Fauci AS Adv Immunol; 1989; 47():377-431. PubMed ID: 2573256 [No Abstract] [Full Text] [Related]
18. How does the HIV escape cytotoxic T cell immunity? Phillips RE; McMichael AJ Chem Immunol; 1993; 56():150-64. PubMed ID: 7680867 [No Abstract] [Full Text] [Related]
19. HIV vaccines: prospects and challenges. Baltimore D; Heilman C Sci Am; 1998 Jul; 279(1):98-103. PubMed ID: 9648305 [No Abstract] [Full Text] [Related]
20. Protection from HIV infection or AIDS? Miedema F; Meyaard L; Klein MR Science; 1993 Nov; 262(5136):1074-6. PubMed ID: 8235627 [No Abstract] [Full Text] [Related] [Next] [New Search]